Fig. 4From: Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experiencePFS was 15.4 months in the bevacizumab group and 6.7 months in the chemotherapy group (P = 0.04)Back to article page